English 
搜索
Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

ProBlad® Verde fungicide receives California CDPR approval for expanded crops and disease uses including blueberries and caneberriesqrcode

Apr. 11, 2024

Favorites Print
Forward
Apr. 11, 2024

Sym-Agro
United States  United States
Follow

Sym-Agro has announced that the California CDPR has approved the expanded crop & disease uses of ProBlad® Verde fungicide. As a result of this approval, ProBlad is now registered for use on Blueberries and Caneberries for the management of disease. This label expansion increases the range of California commercial crops including grapes, almonds, strawberries, tomatoes, and stone fruit.


ProBlad® Verde is an innovative new organic biocontrol that leverages the naturally occurring BLAD polypeptide for a never-before-seen-before, multi-site mode of action that controls fungal & bacterial diseases. What makes ProBlad® Verde unique is that unlike other biochemical fungicides it quickly absorbs into treated plant tissue providing translaminar activity offering both preventative and curative activity towards disease. The result is up to 7 days of reach back activity and up to 14 days of disease prevention. The result is quick, reliable disease control that meets or exceeds established standards. When applied close to harvest this protection helps fruit resist fungal attack during shipping and storage.


ProBlad® Verde is FRAC ″BM01″ fungicide with strong multi-site activity and MRL exempt, helping high value export crop growers meet increasingly stringent standards.


″This expanded registration means that more growers will be able to utilize ProBlad to control disease on their crops,″ said Peter Bierma, Sym-Agro President. ″ProBlad offers a proven and effective solution that is ideal for the needs of today’s growers.″


Source: Sym-Agro

0/1200

More from AgroNewsChange

Hot Topic More

I wanna post a press Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

0/1200

 

NEWSLETTER

Subscribe BioEx Biweekly to send news related to your mailbox